FRONTEO Inc. (Headquarters: Minato-ku, Tokyo, President: Masahiro Morimoto, hereafter FRONTEO) is a medical corporation Tokushukai Shonan Kamakura General Hospital (Location: Kamakura City, Kanagawa Prefecture, Director) : Nobuaki Shinozaki, hereinafter referred to as Shonan Kamakura General Hospital).

 

　Shonan Kamakura General Hospital was established in 1988 and is a regional core hospital with 658 beds, 44 clinical departments, and 2012 staff (as of April 2021, 4). Amanogawa will be used at the hospital's clinical research center. Amanogawa has been introduced mainly by pharmaceutical companies and academia, but this time it will be the first case of introduction in a hospital.

 

　AmanogawaIs a paper search AI system equipped with FRONTEO's original AI engine "Concept Encoder (trademark: concept encoder, reading: concept encoder)".Enter the word, sentence, hypothesis, etc. you want to look up, and AI will instantly detect related papers from the data of more than 3000 million papers published in PubMed *. By utilizing AI, in addition to greatly improving the efficiency of paper search and analysis, which required a huge amount of time for human work, information that could not be found by conventional keyword search and bias by searchers It makes it possible to find information that is not available, and realizes objective and comprehensive analysis in medical and drug discovery research.

 

　FRONTEO aims to make Amanogawa software that can be used in more diverse situations, strives to improve usability and accuracy, and promotes research and development so that it can contribute to the development of medical care and medicine through the provision of AI systems.

 

* PubMed: A database of biomedical papers created by the National Center for Biological Sciences in the National Library of Medicine.

 

■ About FRONTEO　URL:https://www.fronteo.com/
FRONTEO uses the in-house developed AI engines "KIBIT", "Concept Encoder", and "Looca Cross" that specialize in natural language processing to extract meaningful and important information from a huge amount of text data, and is used by companies. A data analysis company that supports business. Since its establishment in August 2003, it has been expanding globally to Japan, the United States, South Korea, and Taiwan, focusing on legal tech businesses such as "e-discovery (electronic discovery)" and "digital forensic investigation" that support corporate international litigation. Has been deployed.Based on the AI ​​technology cultivated in this business, we will expand the business field to the life science field, business intelligence field, and economic security from 8, and by using AI to "turn text data into knowledge", We contribute to solving various corporate issues such as drug discovery support, dementia diagnosis support, financial, personnel, and sales support. Listed on TSE Mothers on June 2014, 2007. Obtained a first-class medical device manufacturing and sales business license in January 6 (permit number: 26B2021X1), and notified the managed medical device sales business in September of the same year (notification number: 13 Minato Misei Equipment No. 1).The capital is 10350 thousand yen (as of March 9, 3).

■ About Concept Encoder　URL:https://lifescience.fronteo.com/technology/conceptencoder/
"Concept Encoder" is a natural language analysis AI (artificial intelligence) developed by FRONTEO specially in the life science field.It was developed in 2018 with the aim of effectively analyzing and utilizing medical data containing a large amount of free-form text data based on evidence. Concept Encoder can be co-analyzed with data other than text, and we are conducting research on co-analysis with numerical data such as gene expression information, vitals, and various test values ​​accumulated in the life science field.Patent registration number: Patent No. 6346367

* FRONTEO, KIBIT, conceptencoder, and Amanogawa are registered trademarks of FRONTEO in Japan.